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Administration of amiodarone (600 to 1,600 mg/day) to
28 patients during long-term digoxin therapy (0.25 ±
0.05 mglday) increased serum digoxin level from 0.97
± 0.45 to 1.98 ± 0.84 nglml (p < 0.001). Gastrointes-
tinal side effects occurred in nine patients, central ner-
vous system reactions occurred in five and cardiovas-
cular reactions occurred in four. Pharmacokinetic studies
in six patients with a 1 mg intravenous digoxin dose
before and during amiodarone therapy increased serum
digoxin level at 30 minutes from 8.59 ± 1.68 to 10.07
:.': 1.70 ng/ml (p < 0.05). Amiodarone caused a 31%
prolongation of digoxin elimination half-life from 49.5
... 8.8 to 65.0 ± 28.8 hours, but the increase in half-
Disorders of cardiac rhythm requiring antiarrhythmic ther-
apy generally develop in patients with heart disease often
with impaired ventricular performance for which cardiac
glycosides are frequently prescribed. Thus, concomitant
therapy with antiarrhythmic drugs and digitalis in many
patients is not unusual. For this reason, pharmacokinetic
interactions between cardiac glycosides and antiarrhythmic
compounds are of more than theoretical importance. An-
tiarrhythmic agents and digoxin exert distinct electrophys-
iologic effects on the heart, which, in combination, may
lead to potentially deleterious effects on cardiac rhythm and
conduction. The above interaction can also result in adverse
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life was not statistically significant. Total body clearance
was reduced significantly (29%, p < 0.05) from 2.05 ±
0,76 to 1.46 ± 0.64 ml/min per kg. Nonrenal clearance
also showed a significant decrease (33%, p < 0.05) from
1.20 ± 0.46 to 0.80 ± 0.30 ml/min per kg. The renal
clearance decreased by 22% and the volume of distri-
bution decreased by 11% after amiodarone therapy, but
these changes were not significant. The data Show that
the mechanism of digoxin-amiodarone interaction is
multifactorial and emphasize the need for close moni-
toring of serum digoxin levels and clinical features dur-
ing concurrent digoxin-amiodarone therapy.
reactions of extracardiac origin. In particular, unexpected
increases in serum digoxin concentrations supervene as a
result of a pharmacokinetic interaction. Such an interaction
has already been demonstrated with digoxin and quinidine
(1-4) and digoxin and verapamil (5).
Our own preliminary studies (6) and those of others (7-11)
have indicated that an important interaction between amio-
darone and therapeutic doses of digoxin can induce side
effects that may closely mimic those of toxic doses of arnio-
darone. This study was undertaken to quantify the magni-
tude of the increase in serum digoxin levels induced by
amiodarone, determine the time course of such an increase
and explore the possible pharmacokinetic mechanisms me-
diating the observed interaction relative to its clinical
significance.
Methods
Study group. Twenty-eight patients receiving mainte-
nance doses of digoxin were given amiodarone for the con-
trol of refractory tachyarrhythmias. Maintenance doses of
digoxin had been constant for at least 2 weeks. In addition,
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in six other patients possible pharmacokinetic mechanisms
were explored. In these six patients, single intravenous in-
jections of digoxin (in accordance with the protocol outlined
later) were given before and after amiodarone treatment.
Concomitant oral digoxin was not given during the entire
period of study. Of the total 34 patients constituting the
study group, 32 were men and 2 were women; 20 had
coronary artery disease, 11 had cardiomyopathy, 2 had atrial
septal defect and 1 had valvular heart disease. All 34 had
normal renal function with clinically stable cardiovascular
hemodynamics. No patients were given other antiarrhythmic
agents concomitantly, nor did they receive other medica-
tions known to interact with cardiac glycosides. The mean
age of the patients was 59 years (range 43 to 84).
Protocol. Study of magnitude of increase in serum di-
goxin levels induced by amiodarone. Trough levels of serum
digoxin were obtained before and after 1 week of continuous
amiodarone treatment in 28 patients treated with mainte-
nance doses of digoxin. The mean (± SO) daily dose of
digoxin for the study group was 0.25 ± 0.05 mg. The dose
of amiodarone varied between 600 to 1,800 mg/day. The
data were collected retrospectively in 16 patients and pro-
spectively in 12. All 28 patients were given digoxin for left
ventricular failure (n = 14), control of supraventricular
tachyarrhythmias (n = 9) and both indications (n = 5).
Determination of time course of increase in serum di-
goxin levels induced by amiodarone . Five patients who had
received a constant dose of digoxin for more than 2 weeks
and in whom amiodarone therapy was considered appro-
priate for the control of refractory ventricular arrhythmias
were admitted to the special diagnostic and treatment unit
for the initiation of therapy and for blood collection for
serum levels of digoxin and amiodarone on the day before
and on days 2,4,6,10 and 16 of amiodarone treatment. Both
digoxin and amiodarone were given at the same time each
day. Blood was drawn every morning, before the admin-
istration of the drug in all patients.
Pharmacokinetic studies. These were carried out in six
patients (five with ventricular and one with supraventricular
tachyarrhythmias) who gave informed consent; they were
admitted to the special diagnostic and treatment unit after
the initial screen tests revealed normal renal function. On
the first day of the study, all six patients were given a 1.0
mg intravenous dose of digoxin over a period of 10 to 20
minutes. Blood samples for digoxin levels were collected
before the intravenous dose and at specific times thereafter
for 96 hours after the intravenous digoxin infusion. Twenty-
four hour urine collections (two aliquots each of 12 hours)
were obtained daily for 4 days after the intravenous digoxin
administration. Commencing on the fifth day, each patient
received 1,600 mg/day of amiodarone for 2 weeks. After
this period, each subject received a second intravenous dose
(1.0 mg) of digoxin, again over a period of 10 to 20 minutes.
Blood and urine samples were obtained in a manner identical
to that described for the control period. Serum samples were
analyzed to determine the concentrations of digoxin, cre-
atinine and amiodarone; urine was analyzed for digoxin and
creatinine.
Analytical methods. Serum and urine concentrations of
digoxin were determined by radioimmunoassay (12) using
a RIANEN digoxin (iodine-125) RIA kit (New England
Nuclear Corp.). Serum levels of amiodarone were deter-
mined by a recent high performance liquid chromatographic
method (13) standardized in our laboratory (14). Serum and
urinary creatinine levels were determined by the Technicon
autoanalyser. Creatinine clearances in the absence and pres-
ence of amiodarone were calculated using pooled data from
the 4 day urine collections.
Data analysis and statistics. Pharmacokinetic variables
were calculated by standard conventional techniques (15).
For each patient, serum digoxin concentration versus time
data were individually fitted to a multiexponential equation
by means of a nonlinear regression computer program and
SAAM analysis. The renal clearance of digoxin was cal-
culated by dividing the amount of digoxin excreted in the
urine over the 4 days after the intravenous dose of the drug
by the area under the plasma concentration time curve for
the same period.
The data were analyzed by the Student's t test for paired
variables and mean values are presented with 1 standard
deviation.
Results
Digoxin levels after amiodarone (Fig. 1 and 2). In
nearly all the 28 patients, substantial increases in serum
levels of digoxin were produced after 1 to 3 weeks of amio-
darone administration. The serum digoxin levels before and
during amiodarone treatment are shown in Figure 1. The
mean increase of 104% (from 0.97 ± 0.48 to 1.98 ± 0.84
ng/m!) for the entire group was statistically significant (p
< 0.001). These changes occurred without a change in the
dose of digoxin (mean 0.25 ± 0.05 mg/day); the mean dose
of amiodarone was 1,251 ± 335 mg/day administered for
a mean of 13.3 ± 5.3 days (range 7 to 21).
The time course of increases in serum digoxin concen-
tration induced by amiodarone concomitantly in five patients
who had already been on a constant dose of digoxin alone
for 4 weeks is shown in Figure 2. The serum digoxin level
increase was parallel with the observed increases in the
levels of serum amiodarone, although the changes in the
levels of the latter demonstrated considerable variability as
indicated by large standard deviations. The increase in the
levels of digoxin induced by amiodarone was apparent within
1 to 2 days of concomitant therapy. However, at a constant
dose of both drugs, new steady state in the levels of serum
digoxin was not attained even after 2 weeks of the com-
bination regimen. The development of side effects or im-
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tration in all patients. Thus, mean total body clearance de-
creased significantly (29%, p < 0.05) from 2.05 ± 0.76
to 1.46 ± 0.64 mllmin per kg. The renal clearance of
digoxin was not affected significantly by amiodarone ther-
apy. The nonrenal clearance, however, showed a significant
decrease (33%, p < 0.05) from 1.20 ± 0.46 to 0.80 ±
0.30 mllmin per kg. Digoxin concentrations were higher in
all six patients when digoxin was given during amiodarone
administration as compared with those under control con-
ditions. The mean concentration measured at 30 minutes
after digoxin injection increased from 8.6 ± 1.7 to 10.1
± 1.7 ng/ml (p < 0.05).
Discussion
Cause of amiodarone-induced reduced digoxin clear-
ance. These results confirm and extend our own prelimi-
nary observations (6) as well as those of others (7-11) that
steady state serum digoxin concentrations increase by at
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Figure 2. Time course of increase in serum digoxin (circles) and
serum amiodarone (triangles) levels in five patients given fixed
doses of digoxin and amiodarone for 16days (after they had been
receiving the samedose of digoxinalonefor the previous 4 weeks).
The data shown are mean values ± standard deviation. Despitea
fixed dose of amiodarone, serum levelscontinue to increase over
the period of observation; during this period. serumdigoxin levels
are augmented, the initial increment being apparent by day 2.
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pending toxicity precluded more protracted observations at
a constant dosage regimen of the two drugs.
Side effects (Table 1). The side effects observed (Table
1) were closely correlated with the increases of serum di-
goxin levels into the toxic range (2.67 ± 0.64 ng/ml),
Despite the high levels of serum digoxin in patients who
developed side effects, digitalis-toxic tachyarrhythmias were
not encountered except in one patient who had an episode
of ventricular fibrillation at a time when the serum digoxin
level was 2.8 ng/ml and potassium was 2.2 mEg/liter. The
adverse effects disappeared in all patients within 3 days
after discontinuation or reduction of digoxin dose.
Pharmacokinetic variables (Table 2). Amiodarone had
no effect on either the serum levels of creatinine or on the
creatinine clearances in six patients in whom detailed phar-
macokinetic studies were carried out. Table 2 summarizes
the pharmacokinetic values derived from the analysis of the
serum and urinary concentrations of digoxin. The elimi-
nation half-life of digoxin was prolonged by 31% from 49.5
± 8.l< to 65.0 ± 28.8 hours after amiodarone, but the
increase was not statistically significant. There was an in-
crease in the half-life of digoxin in all patients except in
Patient 3 whose decreased from 51.0 to 40.7 hours. Values
for the volume of central compartment (Vc) and volume of
distribution (Vd) after amiodarone were not significantly
alterec after amiodarone. There was a consistent decrease
in digoxin total body clearance after amiodarone adminis-
Figure 1. Changes in steady state serum digoxin concentrations
induced by the concomitant administration of amiodarone (600 to
1,600 mg/day; mean 1,251 ± 335) for 7 to 21 days (mean 13.3
± 5.3). Each closed circle represents a value from one patient.
The vertical bars indicate standard deviations from the mean
values. Amiodarone increased digoxin levels in all patients.
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Figure 3. Case2. Semilogarithmic plotof theserum
digoxin concentration as a function of time after the
intravenous administration of digoxin before (open
circles) and during (closed circles) amiodarone
therapy. The lines represent the best nonlinear
regression computer fit to the data.
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Table 1. Side Effects Attributable to Digoxin Toxicity During
Digoxin-Amiodarone Combination Therapy
*Responded to potassiumrepletion and temporarydigoxin withdrawal;
subsequently well controlled on amiodarone therapy. which was initially
instituted when quinidine and procainamidehad failed to control recurrent
ventricular fibrillation or tachycardia. or both.
least 100% when therapy with 600 to 1,600 mg of amio-
darone is initiated and maintained for I week or longer.
Furthermore, our pharmacokinetic data show that amioda-
rone reduces the body clearance of digoxin during concur-
rent therapy by 29% (p < 0.05). If we assume steady state
conditions during long-term therapy, this would mean a 29%
increase in serum digoxin concentrations. However, the in-
crea ses in serum digoxin levels after amiodarone adminis-
tration observed by us and others (6-11) are much greater
than those caused by impaired body clearance. Thus, there
may be other factors involved in amiodarone-digoxin in-
teraction . The significant (33%) reduction in nonrenal clear-
ance would indicate that the metabolism of digoxin by liver
or gut, or both, is modified by amiodarone treatment. Such
a reduction in extrarenal clearance has been reported for
Side Effects
Gastrointestinal (anorexia.
vomiting. constipation)
Central nervous system (weakness.
malaise. visual disturbances)
Cardiac
Sinus arrest and sinus bradycardia
Ventricular fibrillation*
No. of
Patients
9
5
3
I
Digoxin
Level
(ng/ml)
2.7 :!: 0.48
2_9 ± 1.1
2.2 ± 0.5
2.8
quinidine-digoxin interaction (16). The renal clearance of
digoxin decreased by 22% for the whole group, which was
not statistically significant. The creatinine clearance was not
affected by amiodarone treatment in all of the six patients ,
suggesting that glomerular filtration rate was not altered
during concurrent therapy. However , it is known that di-
goxin is eliminated by tubular secretion (17) and the di-
munition in renal clearance may , in part, be explained by
this phenomenon . One other mechanism that may contribute
to the elevated serum digoxin levels with amiodarone is the
displacement from tissue binding sites (especially myocar-
dium) by amiodarone, similar to that reported for quinidine-
digoxin interaction (18,19). This phenomenon may be a
direct effect of amiodarone or may be mediated through
thyroid hormones , the metabolism of which is altered during
long-term amiodarone therapy (20 ,21). In addition, it is
known that the electrophysiologic and pharmacologic effects
of amiodarone in the heart are similar to those in hypothy-
roidism (20) .
Clinical implications. Whatever the mechanisms that
are finally established for the elevation of the steady state
serum digox in concentrations durin g amiodarone therap y,
the clinical significance of such an interaction deserves em-
phasis in view of the increasing use of amiodarone in the
United States for recalcitrant ventricular tachyarrhythm ias
in patient s with ventricular dysfunction needing glycoside
therapy (22-27). We found that increases in serum digoxin
concentration (on a fixed dose of digoxin) during the early
loading doses of amiodarone led to a high incidence of side
effects, mostly of central nervou s system or gastrointestinal
origin; they disappeared as the serum digoxin decreased with
the adjustment of digoxin dosage . In our experience, such
IACC V 11. 4, No.
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Table 2. Pharmacokinetic Variables for Digoxin Disposition Before and During Amiodarone Administration
Digoxin Clearance (mlJmin per kg)
Body TYo(h) V,(1Ikg) Vd(1/kg) Total Body Renal NonrenalWeight
Case (kg) C Amiod C Amiod C Amiod C Amiod C Amiod C Amiod
I 68 40.8 111.0 0.76 0.64 7.17 8.08 2.03 0.84 0.87 0.28 1.16 0.56
2 99 49.6 50.3 0.84 0.57 8.12 7.79 1.90 1.78 0.61 0.76 1.29 1.02
3 82 51.0 40.7 0.99 0.86 9.87 7.16 2.24 2.04 0.83 0.86 1.41 1.18
4 67 27.0 39.9 0.90 0.90 7.87 7.26 3.37 2.16 1.48 1.31 1.89 0.85
5 87 60.2 62.5 1.11 0.70 8.88 7.03 1.70 1.30 0.76 0.47 0.94 0.83
6 93 57.3 81.3 0.70 0.75 5.36 4.78 1.08 0.63 0.55 0.28 0.53 0.35
Mean 49.5 65.0 0.88 0.74 7.88 7.02 2.05 1.46 0.85 0.66 1.20 0.80
± SD 8.8 28.8 0.15 0.13 1.54 1.17 0.76 0.64 0.33 0.39 0.46 0.30
p Value" NS NS NS <0.05 NS <0.05
'C('ntrol versus amiodarone. Amiod = amiodarone; C = control; T'/o = elimination half-life; V, = volume of central compartment; Vd = apparent
volume of distribution.
side effects (except for constipation) are rarely encountered
in the first month of therapy with amiodarone, even with
high closes (27). The high digoxin levels, especially in as-
sociation with hypokalemia that might result from concom-
itant diuretic drug therapy in this context and which may
have occurred in one of our patients, could lead to the early
recurrence of ventricular tachyarrhythmias and might be
responsible for the uncommon cases of torsade de pointes
attributed to amiodarone (28).
The interaction between digoxin and amiodarone re-
ported herein was based on observations at moderate to high
doses of amiodarone given over I to 3 weeks. At the end
of this period when digoxin doses were generally adjusted,
the serum digoxin levels were still increasing at an equal
rate with increases in serum levels of amiodarone at a con-
stant dosage of the two compounds. Clearly, one might
expect less profound changes at lower doses of amiodarone
for a given digoxin regimen. Since loading doses of amio-
darone are now commonly employed for variable periods
at the start of therapy, increases in serum digoxin may reach
toxic levels during this period. Furthermore, it is known
that the elimination half-life of amiodarone is exceedingly
variable and long (14) ranging between 15 to 65 days. Thus,
cumulation of the drug as a function of time even at main-
tenance doses might still lead to a significant interaction
that may become apparent after a lapse of varying durations
of combination therapy. For these reasons, regular deteri-
nation of serum digoxin concentrations with a careful sur-
veillance of the clinical features of toxicity are indicated
when digoxin and amiodarone are given as combination
therapy. The need for such monitoring is clearly most urgent
during the early high dose therapy with amiodarone.
We are grateful to Geetha Sritharan for secretarial assistance, Sandy Miller
for technical assistance, the staff of the Special Diagnostic Treatment Unit
for hell with the care of the patients during the pharmacokinetic studies
and PaJI V. Reicher for illustrations.
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